Total Payments
$2,398
2024 Payments
$543.05
Companies
26
Transactions
149
Medicare Patients
4,069
Medicare Billing
$250,907
Payment Breakdown by Category
Food & Beverage$2,280 (95.1%)
Education$118.26 (4.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,280 | 147 | 95.1% |
| Education | $118.26 | 2 | 4.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $681.22 | 38 | $0 (2024) |
| Novo Nordisk Inc | $404.72 | 22 | $0 (2024) |
| Lilly USA, LLC | $159.00 | 12 | $0 (2024) |
| Merck Sharp & Dohme LLC | $133.78 | 10 | $0 (2024) |
| Sumitomo Pharma America, Inc. | $123.52 | 2 | $0 (2024) |
| PFIZER INC. | $109.76 | 8 | $0 (2024) |
| Sunovion Pharmaceuticals Inc. | $85.32 | 11 | $0 (2018) |
| Amgen Inc. | $78.86 | 5 | $0 (2019) |
| Novartis Pharmaceuticals Corporation | $59.99 | 4 | $0 (2022) |
| Purdue Pharma L.P. | $56.72 | 3 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $543.05 | 19 | AstraZeneca Pharmaceuticals LP ($221.48) |
| 2023 | $203.06 | 14 | AstraZeneca Pharmaceuticals LP ($84.76) |
| 2022 | $361.84 | 19 | Novo Nordisk Inc ($188.55) |
| 2021 | $150.35 | 11 | AbbVie Inc. ($40.19) |
| 2020 | $67.29 | 5 | AstraZeneca Pharmaceuticals LP ($37.29) |
| 2019 | $203.54 | 16 | Merck Sharp & Dohme Corporation ($39.34) |
| 2018 | $264.74 | 21 | AstraZeneca Pharmaceuticals LP ($113.81) |
| 2017 | $604.44 | 44 | AstraZeneca Pharmaceuticals LP ($122.53) |
All Payment Transactions
149 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/06/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $13.33 | General |
| Category: Obesity | ||||||
| 11/01/2024 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $21.75 | General |
| Category: Biological | ||||||
| 10/16/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $15.79 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/07/2024 | Merck Sharp & Dohme LLC | LAGEVRIO (Drug) | Food and Beverage | In-kind items and services | $19.66 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 10/04/2024 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $18.40 | General |
| Category: Biological | ||||||
| 08/20/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $14.61 | General |
| Category: Diabetes | ||||||
| 08/20/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $13.52 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 07/09/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $15.19 | General |
| Category: Diabetes | ||||||
| 06/03/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Food and Beverage | In-kind items and services | $15.54 | General |
| Category: Obesity | ||||||
| 05/01/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $138.83 | General |
| Category: Respiratory | ||||||
| 04/15/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug), FARXIGA, BREZTRI | Food and Beverage | In-kind items and services | $37.86 | General |
| Category: Respiratory | ||||||
| 04/09/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $15.48 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 03/25/2024 | PFIZER INC. | ELIQUIS (Drug), PAXLOVID, NURTEC ODT | Food and Beverage | In-kind items and services | $20.56 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 03/18/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $14.96 | General |
| Category: Obesity | ||||||
| 03/11/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $13.88 | General |
| Category: PAIN | ||||||
| 03/06/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $17.89 | General |
| Category: Diabetes | ||||||
| 02/26/2024 | IBSA Pharma Inc. | Tirosint (Drug), Licart | Food and Beverage | Cash or cash equivalent | $14.65 | General |
| Category: Endocrinology | ||||||
| 02/12/2024 | Sumitomo Pharma America, Inc. | GEMTESA (Drug) | Food and Beverage | In-kind items and services | $106.85 | General |
| Category: UROLOGY | ||||||
| 01/29/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Food and Beverage | In-kind items and services | $14.30 | General |
| Category: Obesity | ||||||
| 12/04/2023 | Sumitomo Pharma America, Inc. | GEMTESA (Drug) | Food and Beverage | In-kind items and services | $16.67 | General |
| Category: UROLOGY | ||||||
| 11/20/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $13.54 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/23/2023 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $14.18 | General |
| Category: Diabetes | ||||||
| 10/09/2023 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $15.93 | General |
| Category: Cardiovascular | ||||||
| 09/11/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $13.32 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 08/14/2023 | IBSA Pharma Inc. | LICART (Drug), TIROSINT, TIROSINT | Food and Beverage | Cash or cash equivalent | $15.90 | General |
| Category: non-opioid analgesic | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 805 | 1,176 | $158,800 | $44,206 |
| 2022 | 17 | 1,098 | 1,759 | $239,489 | $64,403 |
| 2021 | 16 | 1,109 | 1,744 | $234,434 | $82,428 |
| 2020 | 13 | 1,057 | 1,556 | $187,338 | $59,870 |
Total Patients
4,069
Total Services
6,235
Medicare Billing
$250,907
Procedure Codes
55
All Medicare Procedures & Services
55 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 209 | 446 | $79,388 | $22,239 | 28.0% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 102 | 102 | $22,644 | $6,397 | 28.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 59 | 71 | $20,519 | $3,839 | 18.7% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2023 | 42 | 42 | $5,559 | $3,172 | 57.1% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 79 | 83 | $5,587 | $2,820 | 50.5% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 33 | 37 | $4,300 | $2,596 | 60.4% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 203 | 302 | $12,382 | $2,516 | 20.3% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 34 | 36 | $6,084 | $433.36 | 7.1% |
| 81002 | Urinalysis, manual test | Office | 2023 | 44 | 57 | $2,337 | $194.37 | 8.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 211 | 461 | $82,058 | $23,122 | 28.2% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 145 | 145 | $32,190 | $8,429 | 26.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 102 | 149 | $43,061 | $8,376 | 19.5% |
| 99308 | Follow-up nursing facility visit per day, typically 15 minutes | Office | 2022 | 18 | 145 | $27,115 | $8,006 | 29.5% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 95 | 96 | $4,704 | $3,238 | 68.8% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2022 | 52 | 54 | $3,245 | $3,184 | 98.1% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2022 | 38 | 39 | $2,340 | $2,294 | 98.1% |
| 99495 | Transitional care management services for problem of moderate complexity | Office | 2022 | 20 | 25 | $5,750 | $1,670 | 29.0% |
| 99305 | Initial nursing facility visit per day, typically 35 minutes | Office | 2022 | 11 | 13 | $3,991 | $1,452 | 36.4% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 230 | 392 | $16,072 | $1,162 | 7.2% |
| 87811 | Detection test by immunoassay with direct visual observation for severe acute respiratory syndrome coronavirus 2 (covid-19) | Office | 2022 | 22 | 25 | $1,000 | $984.80 | 98.5% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2022 | 12 | 18 | $1,656 | $764.56 | 46.2% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 51 | 54 | $9,126 | $659.65 | 7.2% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 11 | 31 | $2,387 | $364.34 | 15.3% |
| 81002 | Urinalysis, manual test | Office | 2022 | 52 | 83 | $3,403 | $285.71 | 8.4% |
| 87804 | Detection test by immunoassay with direct visual observation for influenza virus | Office | 2022 | 13 | 14 | $896.00 | $228.21 | 25.5% |
About Dr. Paul Madura, MD
Dr. Paul Madura, MD is a General Acute Care Hospital healthcare provider based in Hampton, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/12/2006. The National Provider Identifier (NPI) number assigned to this provider is 1144255506.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Paul Madura, MD has received a total of $2,398 in payments from pharmaceutical and medical device companies, with $543.05 received in 2024. These payments were reported across 149 transactions from 26 companies. The most common payment nature is "Food and Beverage" ($2,280).
As a Medicare-enrolled provider, Madura has provided services to 4,069 Medicare beneficiaries, totaling 6,235 services with total Medicare billing of $250,907. Data is available for 4 years (2020–2023), covering 55 distinct procedure/service records.
Ad
Practice Information
- Specialty General Acute Care Hospital
- Other Specialties Family Medicine
- Location Hampton, NJ
- Active Since 07/12/2006
- Last Updated 07/11/2009
- Taxonomy Code 282N00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1144255506
Products in Payments
- FARXIGA (Drug) $478.29
- Ozempic (Drug) $217.19
- AIRSUPRA (Drug) $176.69
- GEMTESA (Drug) $123.52
- TRULICITY (Drug) $90.83
- Saxenda (Drug) $84.32
- Prolia (Biological) $66.90
- ENTRESTO (Drug) $59.99
- NURTEC ODT (Drug) $59.36
- JANUVIA (Drug) $52.98
- BROVANA (Drug) $51.19
- Victoza (Drug) $44.52
- JARDIANCE (Drug) $44.10
- TOUJEO (Drug) $40.47
- Veozah (Drug) $40.15
- TRINTELLIX (Drug) $39.81
- VRAYLAR (Drug) $39.38
- ELIQUIS (Drug) $36.49
- XARELTO (Drug) $34.11
- Rybelsus (Drug) $30.40
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.